Contrast media and cutaneous reactions. Part 1. Immediate hypersensitivity reactions to contrast media and gadolinium deposition.
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
accepted:
14
03
2019
pubmed:
22
5
2019
medline:
28
3
2020
entrez:
22
5
2019
Statut:
ppublish
Résumé
Contrast media (CM) are commonly used worldwide to enhance the quality of imaging, which is invaluable for diagnostic accuracy. Adverse reactions to CM are uncommon, but frequently involve cutaneous symptoms. This two-part article reviews adverse events secondary to CM that are relevant to the practising dermatologist. Part 1 will classify CM, address immediate hypersensitivity reactions and review the newly described condition, gadolinium deposition disease. Part 2 will cover the delayed hypersensitivity reactions of iodinated contrast medium including severe cutaneous adverse reactions and iododerma.
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-843Informations de copyright
© 2019 British Association of Dermatologists.
Références
Christiansen C. X-ray contrast media-an overview. Toxicology 2005; 209: 185-7.
Lusic H, Grinstaff MW. X-ray-computed tomography contrast agents. Chem Rev 2013; 113: 1641-66.
Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Investig Allergol Clin Immunol 2016; 26: 144-55.
ACR Manual on Contrast Media, version 10.3, 2017. Available at: https://www.acr.org/-/media/ACR/files/clinical-resources/contrast_media.pdf (accessed 19 March 2019).
Frenzel T, Lengsfeld P, Schirmer H et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008; 43: 817-28.
Clement O, Dewachter P, Mouton-Faivre C et al. Immediate hypersensitivity to contrast agents: the French 5-year CIRTACI Study. EClinicalMedicine 2018; 1: 51-61.
Katayama H, Yamaguchi K, Kozuka T et al. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175: 621-8.
Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001; 176: 1385-8.
Mortele KJ, Oliva MR, Ondategui S et al. Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital. AJR Am J Roentgenol 2005; 184: 31-4.
Prince MR, Zhang H, Zou Z et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011; 196: W138-43.
Jung JW, Kang HR, Kim MH et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 2012; 264: 414-22.
Aran S, Shaqdan KW, Abujudeh HH. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections. Clin Radiol 2015; 70: 466-75.
Runge VM. Safety of magnetic resonance contrast media. Top Magn Reson Imaging 2001; 12: 309-14.
Webb JA, Stacul F, Thomsen HS, Morcos SK. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol 2003; 13: 181-4.
Brockow K, Romano A, Aberer W et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2009; 64: 234-41.
Yoon SH, Lee S-Y, Kang H-R et al. Skin tests in patients with hypersensitivity reaction to iodinated contrast media: a meta-analysis. Allergy 2015; 70: 625-37.
Davenport MS, Cohan RH. The evidence for and against corticosteroid prophylaxis in at-risk patients. Radiol Clin North Am 2017; 55: 413-21.
Macy EM. Current epidemiology and management of radiocontrast-associated acute- and delayed-onset hypersensitivity: a review of the literature. Perm J 2018; 22: 17-072.
Freed KS, Leder RA, Alexander C et al. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol 2001; 176: 1389-92.
Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal- dialysis patients. Lancet 2000; 356: 1000-1.
Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.
Zhang B, Liang L, Chen W et al. An updated study to determine association between gadolinium-based contrast agents and nephrogenic systemic fibrosis. PLoS One 2015; 10: e0129720.
Malikova H, Holesta M. Gadolinium contrast agents - are they really safe? J Vasc Access 2017; 18 (Suppl. 2): 1-7.
European Medicines Agency (EMA). Gadolinium-containing contrast agents. Availabe at: https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents (accessed 10 January 2019).
Semelka RC, Ramalho M, Jay M. Summary of special issue on gadolinium bioeffects and toxicity with a look to the future. Magn Reson Imaging 2016; 34: 1399-401.
Semelka RC, Ramalho J, Vakharia A et al. Gadolinium deposition disease: initial description of a disease that has been around for a while. Magn Reson Imaging 2016; 34: 1383-90.
Ramalho M, Ramalho J, Burke LM, Semela RC. Gadolinium retention and toxicity: an update. Adv Chronic Kidney Dis 2017; 24: 138-46.
Semelka RC, Commander CW, Jay M et al. Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases. Invest Radiol 2016; 51: 661-5.
Gathings RM, Reddy R, Santa Cruz D, Brodell RT. Gadolinium-associated plaques: a new, distinctive clinical entity. JAMA Dermatol 2015; 151: 316-19.